drugset / Trial / NCT04440735
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.
Timeline
- Start
- 2020-10-07
- Primary completion
- 2025-09
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | DSP107 | Protein / enzyme biologic | 0.01 mg/kg | Intravenous |
| Subject | DSP107 | Protein / enzyme biologic | 10 mg/kg | Intravenous |